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ABSTRACT
Background: Esophageal variceal hemorrhage is a devastating complication of portal 
hypertension that occurs in approximately one-third of cirrhotic patients. 
Objectives: We assessed the value of the platelet count/ bipolar spleen diameter ratio 
as a noninvasive parameter for the prediction of esophageal varices (EVs) in Egyptian 
cirrhotic patients.
Patients and Methods: Laboratory and ultrasonographic and imaging variables were 
prospectively evaluated in 175 patients with liver cirrhosis. All patients underwent up-
per gastrointestinal endoscopy. Patients with active gastrointestinal bleeding at the 
time of admission were excluded.
Results: The platelet count/ bipolar spleen diameter ratio in patients with EVs was sig-
nificantly lower than in patients without EVs. In an analysis of the receiver operating 
characteristic curves (ROCs), we calculated an optimal cutoff value of 939.7 for this ra-
tio, which gave 100% sensitivity and negative predictive values, 86.3% specificity, a 95.6% 
positive predictive value, and an area under the ROC curve of 0.94 ± 0.02, reflecting 
its overall diagnostic accuracy. These findings were extended to a subset analysis of 
compensated cirrhotic patients.
Conclusions: The platelet count/ bipolar spleen diameter ratio has excellent accuracy in 
the noninvasive assessment of EVs in patients with compensated or decompensated 
liver cirrhosis. It is easy to calculate and can lower the financial and sanitary burdens 
of endoscopy units, especially in developing countries.
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Background
Portal hypertension and esophageal varices (EVs) are 
common  major  complications  of  liver  cirrhosis,  oc-
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extremely high mortality rate (1-3). Therefore, the pre-
vention of variceal bleeding is an important goal in man-
agement  patients  with  liver  cirrhosis.  Universal  endo-
scopic screening of EVs is recommended in conjunction 
with primary prophylaxis in patients who are at high 
risk of variceal bleeding (4, 5). But, this screen is invasive, 
and many patients will not have varices, rendering this 
method cost-ineffective. Thus, noninvasive diagnosis of 
portal hypertension may be useful (2). Recently, several 
studies have attempted to identify the variables that can 
predict the presence of EVs—even large EVs—noninvasive-
ly,  examining  various  biochemical,  clinical,  and  ultra-
sonographic parameters alone or in combination, with 
promising results overall (6-9).
Most such variables, however, have several limitations, 
which has hindered the wide application of these results. 
Early studies were retrospective and were performed in a 
specific subgroup of patients—those who were going to 
be placed on a wait list for liver transplantation (8, 10-14); 
thus, the study groups lacked homogeneity and the wide 
representation of the cirrhotic population that is seen in 
clinical practice. Further, in patients with chronic liver 
disease, although the presence of thrombocytopenia is 
due  primarily  to  portal  hypertension  (15),  thrombocy-
topenia can depend on other factors, such as shortened 
mean  platelet  lifetime,  decreased  thrombopoetin  pro-
duction, and the myelotoxic effects of alcohol or hepati-
tis viruses (16); thus, the autoimmune profile and bone 
marrow aspirate should be assessed for greater accuracy 
before conclusions can be made on the final data that 
thrombocytopenia is owing to liver cirrhosis.
Finally, there has been a lack in uniformity in the classi-
fication and diagnosis of EVs in previous studies (8, 10-14), 
in which EVs were not categorized by a single endosco-
pist or in the same endoscopy unit. Moreover, their focus 
on patients with large EVs might have led to the omission 
of an important subset of patients who required medical 
counseling; thus, the analysis of the presence or absence 
of  EVs  might  prevent  data  from  being  misinterpreted 
and  allow  results  to  be  generalized  (15).  The  platelet 
count:spleen diameter ratio, proposed by Giannini et al. 
(15), appears to be one of the best noninvasive predictors 
of EVs that have emerged (17).
Objectives
In  this  prospective  study,  we  evaluated  the  platelet 
count:spleen diameter ratio in 175 consecutive unselect-
ed Egyptian cirrhotic patients—with varying ethnicities 
and clinical presentations and poor nutritional status, 
many of whom had a viral etiology—in predicting EVs.
Patients and Methods
Eligible patients
This study included 175 consecutive patients with liver 
cirrhosis due to hepatitis C virus. Liver cirrhosis was di-
agnosed by physical, laboratory, and radiological evalua-
tions. Diagnosis was confirmed by histological examina-
tion of Tru-cut needle-isolated liver biopsy for patients 
with Child-Pugh class A. After written consent was ob-
tained, the participants underwent upper GIT endoscopy 
in  our  endoscopy  unit,  Minia  University  Hospital,  be-
tween April 2008 and March 2010. The exclusion criteria 
were: active variceal bleeding at admission, a history of 
endoscopic variceal sclerotherapy or band ligation, tran-
sjugular intrahepatic portosystemic stent shunt place-
ment, a history of surgery for portal hypertension, medi-
cation use for primary prophylaxis of variceal bleeding, 
alcohol  abuse,  and  thrombocytopenia  due  to  causes 
other than hypersplenism. Other complications of liver 
cirrhosis were not exclusion criteria, although they were 
recorded.
Informed consent
The study protocol was approved by the Institutional 
Ethics Committee of the School of Medicine, Minia Uni-
versity, Egypt, and all patients gave their informed con-
sent to participate. The study was conducted in accor-
dance with the ethical guidelines of the 1975 Declaration 
of Helsinki and the International Conference on Harmo-
nization Guidelines for Good Clinical Practice.
Clinical and Laboratory Assessment
At the time of the upper endoscopy, a history was taken 
and a clinical examination was performed, with special 
emphasis on the stigmata of chronic liver disease and 
a careful abdominal examination. After hospital admis-
sion, venous blood was drawn to determine the complete 
blood count, prothrombin time and concentration, liver 
function, and renal function. In thrombocytopenic pa-
tients (platelets < 140,000/cmm), anti-nuclear antibody 
(ANA), anti-smooth muscle antibody (ASMA), and gam-
ma-globulin levels were measured and bone marrow as-
piration was performed to exclude causes of thrombocy-
topenia other than portal hypertension.
Imaging Study
Abdominal ultrasonography: Cirrhosis was diagnosed 
per the criteria of Tchelepi et al. (18). Maximum bipolar 
spleen diameter was measured by ultrasonography and 
expressed in millimeters per Lamb et al. (19). The platelet 
count/ bipolar splenic diameter ratio was calculated for 
all patients. Duplex study of the portal vein: Mean portal 
blood flow velocity (MPBV) was measured in the portal 
vein trunk per Mori Yasu et al. (20) and expressed in the 
Duplex Doppler system as V mean. After these evalua-
tions were completed, all cirrhotic patients were classi-
fied per Child-Pugh's criteria (21), and their scores were 
calculated.
Upper Endoscopy
Patients were evaluated for the presence of EVs, gas-Hepat Mon. 2011;11(4):278-284
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tropathy, and other findings. All endoscopies were per-
formed by a single expert endoscopist who was blinded 
to the patient's data.
Statistical analysis
All data were tabulated. SPSS® (USA) version 11 was used 
for the statistical analysis. A descriptive analysis was per-
formed for all data. Numerical data were expressed as 
mean ±SD and range, and categorical data were expressed 
as number and percentage. T-test was used to compare 2 
independent groups of data. Chi-square test was used to 
compare categorical groups of data. Multivariate logistic 
regression analysis was performed on parameters that 
differed significantly in the univariate analysis between 
patients with no EVs and those with EVs to determine the 
variables that were independently associated with the 
presence of EVs. Receiver operating characteristic (ROC) 
curves were generated to determine the cutoff values for 
the best sensitivity and specificity of the variables with 
regard to the presence of EVs. Also, the ROC curves were 
used to identify the cutoff prevalence-adjusted negative 
and positive predictive values for the presence of EVs. The 
validity of the model was determined using the concor-
dance (c) statistic (equivalent to the area under the ROC 
curve). A model with a c-value above 0.7 is considered to 
be useful, and a c-value between 0.8 and 0.9 indicates ex-
cellent diagnostic accuracy. A P-value was considered to 
be nonsignificant if > 0.05 and significant if ≤ 0.05.
Results
Frequency of EVs and Correlation with Clinical, Labora-
tory, and Radiology Findings 
One hundred fifteen men and 60 women were includ-
ed in the study. The mean age was 48 years (range 36–60 
years). Forty-six patients were Child-Pugh class A (26.3%), 
59 were class B (33.7%), and 70 were class C (40%). EVs 
were detected in 131 patients (74.9%). Further, EVs were 
observed in 14 (30.4%) in the 46 patients with compen-
sated  cirrhosis.  The  presence  of  EVs  correlated  signifi-
cantly with the severity of liver cirrhosis (p = 0.001), as 
measured  by  Child-Pugh  score  (Table  1).  Patients  with 
EVs were older; had lower platelet counts; higher Child-
Pugh scores; developed hepatic encephalopathy, ascites, 
and jaundice more frequently; and had lower prothrom-
bin concentrations, lower platelet count/bipolar spleen 
Variables Patients with EVs a 
(No. = 131) (74.9%)
Patients without EVs a 
(No. = 44) (25.1%)
p-value
Child A  14 (10.7%) 32 (72.7%)
0.001  Child B  52 (39.7%) 7 (15.9%)
Child C  65 (49.6%) 5 (11.4 %)
Table 1. Distribution of patients with and with esophageal varices by Child-Pugh score 
a EVs = esophageal varices. Data are expressed as numbers and percentages and compared by chi-square test.
Variables Cirrhotics with EVs a 
(No. = 131)
Cirrhotics without EVs a 
(No. = 44)
p-value
Age ( years)  51.09 ± 5.1 46.8 ± 7.9 0.001 
Sex 
Male (%) 
Female (%)
83 (63.4 %)
48 (36.6 %)
32 (72.7 %) 
12 (27.3%)
0.2
Splenomegaly (%) 131 (100%) 44 (100 %)     _
Child-Pugh  score 9.8 ± 2.8 6.8 ± 2.3 0.001
Platelet count (No/cmm) 119480.9 ± 38725.7  213000 ± 69232.6  0.001
Table 2. Demographic, clinical, and laboratory characteristics of cirrhotics with and without esophageal varices 
a EVs = esophageal varices
Variables Cirrhotics with EVs c 
(No. =131)
Cirrhotics without EVs c 
(No. = 44)
p-value
PVD a (mm)  13.04 ± 1.9 12.4 ± 2.0 0.07
Bipolar spleen diameter (mm) 159.4 ± 24.2 140.5 ± 20.7 0.001 
Platelet count/bipolar spleen diameter 
ratio 
747.6 ± 197.6 1588.8 ± 744.9 0.001 
MPBV b  12.8 ± 2.2 12.8 ± 2.8 0.9
Table 3. Characteristics of imaging study in cirrhotics with and without esophageal varices
a PVD = portal vein diameter
b MPBV = mean portal blood velocity
c EVs = esophageal varices Hepat Mon. 2011;11(4):278-284
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diameter  ratios,  and  higher  bipolar  spleen  diameters 
(Tables 1, 2, 3). Although patients with EVs had higher por-
tal vein diameter PVDs and mean portal blood velocity, 
these findings were not significant (p = 0.07, p = 0.9; re-
spectively) (Table 3).
Factors Associated with EVS by Multivariable Analysis
In  the  multivariate  ordinal  regression  analysis,  the 
presence of EVs was associated significantly with plate-
let count: spleen diameter ratio (odds ratio; 1.028, 95% 
CI: 1.016-1.04, P = 0.001) and age (odds ratio; 1.205, 95% 
CI: 1.043-1.392, P = 0.01) (Table 4). The area under the ROC 
curve for the platelet count/ bipolar spleen diameter ra-
tio was 0.94 ± 0.02 (Figure 1), which represents the overall 
diagnostic accuracy of the ratio in predicting EVs. Thus, 
on random selection of an individual with EVs versus no 
EVs, the score of the former will be lower 94% of the time. 
Table 5 shows the sensitivity, specificity, PPV, and NPV of 
the ratio at various cutoff levels. At a score of 939.7, the 
ratio has high sensitivity (100%), robust negative predic-
tive value NPV (100%), and high specificity (86.3%) and 
positive predictive value PPV (95.6%). 
In a separate analysis, the platelet count/bipolar spleen 
diameter ratio was significantly higher in compensated 
cirrhotics  (Child-Pugh  class  A)  without  EVs  compared 
with those with EVs (1802 ± 987 and 770 ± 146.6, respective-
ly; p = 0.0001). In this analysis, the ratio maintained high 
sensitivity (100 %), robust NPV (100%), and high specificity 
(81.8%) and PPV (97%), with an overall diagnostic accuracy 
of 87.2% (Table 6). Notably, none of the thrombocytopenic 
patients showed any evidence of thrombocytopenia for 
etiologies other than hypersplenism, as evidenced by the 
normal  results  for  ANA,  ASMA,  gamma-globulin  levels 
and bone marrow aspiration (data not shown). 
Discussion
Management of EVs is an everyday challenge. Current 
guidelines recommend that all patients should undergo 
endoscopic screening for varices when cirrhosis is diag-
nosed, after which patients with medium and large va-
rices should be treated to prevent bleeding. For all other 
patients, regular periodic evaluation is required (22). In 
Egypt, however, the management of patients with liver 
Predictor Regression coefficient  Odds ratio 95% CI p-value
Platelet count/bipolar spleen diameter ratio  0.633 1.028 1.016-1.041 0.001
Age  0.150 1.205 1.043-1.392 0.01
Table 4. Best-fitting multiple logistic regression predictors of esophageal varices 
Cutoff value Sensitivity Specificity NPV a PPV b Accuracy
939.7 100% 86.3% 100% 95.6% 96.5%
Table 5. Predictive accuracy of the best cutoff value of platelet count/ bipolar spleen diameter ratio in the diagnosis of esophageal varices 
a NPV = negative predictive value
b PPV = positive predictive value
 Table 6. Validation of cutoff value of platelet count/ bipolar spleen diam-
eter ratio in the diagnosis of esophageal varices in patients with compen-
sated liver cirrhosis
a NPV = negative predictive value
b PPV = positive predictive value
Sensitivity Specificity NPV a PPV b Accuracy
100% 81.8 % 100 % 70 % 87.2 %
cirrhosis complicated by the interplay between clinical, 
economic, social, and cultural factors and the generally 
poor compliance to both follow-up and treatment strat-
egies. Endoscopic follow-up, which is recommended by 
international guidelines, is not feasible in most patients 
for many reasons. Liver diseases are common in Egypt 
due to the higher prevalence of viral hepatitis (23, 24) 
and increased incidence of schistosomiasis (25); more-
over, most patients present in the late phase of liver dis-
ease. Further, the majority of patients is uninsured and 
must pay for expenses out of pocket, unaware of the risk 
of the variceal bleeding, and they are apparently healthy 
asymptomatic  compensated  patients.  Compliance  can 
also be limited, because it requires that patients who are 
asymptomatic undergo a procedure repeatedly that is 
perceived to be unpleasant.
Endoscopic follow-up is also impractical due to the fear 
of infection; despite efforts to ensure sterilization, there 
remains a risk of re-infection by another subtype of the 
same virus infect the patient or another viral hepatitis 
with increased risk of decompensation in compensated 
patients (26). Finally, endoscopy units are not available 
in all hospitals, particularly in rural areas, necessitating 
other easier modalities for the diagnosis and monitor-
ing of portal hypertension. Thus, a method of predicting 
the presence of EVs noninvasively is in great demand to 
avoid  unnecessary  endoscopy  and  improve  the  cost-
effectiveness of management; the latter is a particularly 
important  consideration  in  many  African  and  Middle 
Eastern countries, including Egypt, where liver cirrho-
sis is highly prevalent. Ideally, a method for identifying 
patients with varices should be simple, noninvasive, in-
expensive, reproducible, accurate, and readily available; 
have high sensitivity and specificity; follow the natural 
history;  reflect  the  effect  of  the  treatment  accurately; 
and  indicate  the  prognosis  and  possibility  of  the  suc-
cess of a treatment. Several noninvasive and minimally Hepat Mon. 2011;11(4):278-284
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invasive methods have emerged in recent years, assess-
ing the potential of various laboratory, clinical, and ul-
trasonographic parameters, linked directly or indirectly 
to portal hypertension, such as splenomegaly, decreased 
platelet count, and portal vein diameter (8-10, 22, 27-31). 
Three  such  methods  have  been  examined  extensively: 
platelet count:spleen diameter ratio (15), Fibrotest (32), 
and Fibroscan (33). Fibrotest appears to be insufficiently 
precise, and Fibroscan requires further evaluation; nei-
ther test is widely available in Egypt due to financial and 
technical considerations. In a seminal trial, Giannini and 
colleagues used the platelet count:spleen diameter ratio 
as a parameter, linking thrombocytopenia to spleen size 
to predict portal hypertension (15). Although these inter-
national trials; the differences in the populations charac-
ters and the need to a well-designed repeated multiple 
large multi-central trials, before any final recommenda-
tion can be concluded, lead to that the conclusions of the 
Baveno IV consensus workshop on portal hypertension 
were that, endoscopic screening has been the optimal 
method of detecting varices (4, 5). For these reasons, we 
planned the current study to evaluate the use of a similar 
ratio in Egyptian cirrhotic patients who typically present 
late and have varying ethnicities, poorer nutritional sta-
tus, and significant viral etiology to overcome the draw-
backs of previous studies. (We think that this paragraph 
doesn’t need modification).
In our study, the prevalence of EVs was 74.9%, which 
might be attributed to the late presentation of our pa-
tients  and  the  increased  incidence  of  schistosomiasis 
in our region (25). In addition to age, serum bilirubin, 
prothrombin  activity,  platelet  count,  spleen  diameter, 
and  Child-Pugh  scores,  the  platelet  count:spleen  di-
ameter ratio was associated with portal hypertension. 
These  results  were  confirmed  by  multivariate  logistic 
regression, which demonstrated that the platelet count: 
spleen diameter ratio (odds ratio: 1.028, 95% CI: 1.016-1.04, 
P = 0.001) and age were independent predictive factors 
for EVs (odds ratio: 1.205, 95% CI: 1.043-1.392, P = 0.01). Al-
though portal vein diameter, as assessed by ultrasonog-
raphy,  was  higher  in  cirrhotic  patients  with  EVs,  this 
correlation  failed  to  reach  statistical  significance  (P  = 
0.07), as did mean portal blood flow velocity; these data 
are consistent with results of other large trials (8, 10-14). 
Moreover,  performing  Doppler  sonographic  examina-
tion requires sophisticated skills and equipment, limit-
ing its value in the identification of patients with cirrho-
sis who are at risk of variceal bleeding (34). Our analysis 
of the area under the ROC curve (AUROC) revealed that 
the  cutoff  of  the  platelet  count:spleen  diameter  ratio 
(939.7) was the optimal value for accurate prediction of 
EVs with an AUC of 0.95; this value corresponded to posi-
tive and negative predictive values of 96% and 100%, re-
spectively. It has been reported that a negative predictive 
value (NPV) of 100% is desirable for screens to minimize 
the oversight of individuals who are at risk (13, 17). This 
finding is consistent with the initial study by Giannini 
et al. (15), who used a cutoff of 909 with an AUROC curve 
of 0.981, corresponding to positive and negative predic-
tive values of 95.6% and 100%, respectively, for the pres-
ence of varices. The same ratio has also been examined by 
many groups in many countries in patient populations 
that differed from the group in which it was developed, 
generating consistent results—suggesting that the ratio 
is generalizable (35-38). We believe that this ratio is valu-
able and unique—a hypothesis that is supported by many 
clinical, financial, and statistical findings. Clinically, the 
increase in spleen size in patients with chronic liver dis-
ease is nearly always a manifestation of portal hyperten-
sion  (39,  40);  conversely,  although  thrombocytopenia 
can result from immune-mediated mechanisms or lower 
thrombopoietin synthesis (16, 41), in most cases it is usu-
ally caused by splenic pooling of platelets due to portal 
hypertension  (15,  42).  This  model  is  supported  by  our 
results,  in  which  thrombocytopenia  was  attributed  to 
hypersplensim in all patients. Integrating platelet count 
and spleen size in a ratio allowed us to determine the ex-
tent of thrombocytopenia that most likely resulted from 
hypersplenism. Financially, the ratio is easy to calculate 
and can be used at the bedside, Biannual calculation of 
the ratio will not generate additional costs in the man-
agement of cirrhotic patients, because platelet count is 
assessed  routinely  and  abdominal  ultrasonography  is 
usually performed at least semiannually to monitor he-
patocellular carcinoma (43). In fact, spleen bipolar mea-
surements consistently show high reproducibility and 
low intra- and interobserver variability (44, 45).
Statistically,  the  platelet  count:spleen  diameter  ratio 
and age were the only parameters that were indepen-
dently associated with the presence of EVs in the multi-
variate analysis. The AUROC curves for age and platelet 
count:spleen diameter ratio were 0.31 and 0.95, respec-
tively, indicating that the ratio can be used as the sole 
predictive factor for EVs. Notably, in a subset analysis, 
Figure 1. Receiver operating characteristic curve (roc) of platelet count/ bi-
polar spleen diameter ratio and age 
AUC = area under the curve
AUC for ratio = 0.94 ± 0.02, AUC for age = 0.33 ± 0.05
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this  ratio  remained  valuable  in  the  prediction  of  the 
presence of EVs in patients with no signs of decompensa-
tion, with 100% sensitivity and NPV. This property might 
be particularly useful; its clinical importance has recent-
ly been emphasized (3, 10, 46, 47). Although our results 
were based on a subset analysis and in smaller sample 
sizes,  routine  periodic  endoscopy,  as  recommended 
by the Ministry of National Health in Egypt, should be 
considered in the follow-up of cirrhotic patients; based 
on limitations in financial resources, this sample ratio; 
platelet count:spleen diameter ratio should be applied.
In conclusion, the platelet count:spleen diameter ratio 
is an accurate noninvasive method of assessing EVs in 
Egyptian patients with compensated or decompensated 
liver cirrhosis. It is easy to calculate and can reduce the 
financial and sanitary burdens of endoscopy units, par-
ticularly in developing countries. Additional large multi-
center studies on this ratio should be performed. 
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